These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16414084

  • 21. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition.
    Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, Ghosh P, Moran A, Predergast MM, Tromp G, Williams CJ, Inohara N, Núñez G.
    EMBO J; 2004 Apr 07; 23(7):1587-97. PubMed ID: 15044951
    [Abstract] [Full Text] [Related]

  • 22. [Bone destruction caused by osteoclasts].
    Yamashita T, Takahashi N, Yang S, Sato N, Udagawa N.
    Clin Calcium; 2006 Feb 07; 16(2):234-40. PubMed ID: 16465024
    [Abstract] [Full Text] [Related]

  • 23. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
    Tada H, Aiba S, Shibata K, Ohteki T, Takada H.
    Infect Immun; 2005 Dec 07; 73(12):7967-76. PubMed ID: 16299289
    [Abstract] [Full Text] [Related]

  • 24. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients.
    Adib-Conquy M, Adrie C, Fitting C, Gattolliat O, Beyaert R, Cavaillon JM.
    Crit Care Med; 2006 Sep 07; 34(9):2377-85. PubMed ID: 16850005
    [Abstract] [Full Text] [Related]

  • 25. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype.
    Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G.
    Genes Immun; 2008 Apr 07; 9(3):274-8. PubMed ID: 18340358
    [Abstract] [Full Text] [Related]

  • 26. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.
    Dugan J, Griffiths E, Snow P, Rosenzweig H, Lee E, Brown B, Carr DW, Rose C, Rosenbaum J, Davey MP.
    J Immunol; 2015 Jan 01; 194(1):349-57. PubMed ID: 25429073
    [Abstract] [Full Text] [Related]

  • 27. Synergistic enhancement of Toll-like receptor responses by NOD1 activation.
    van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, Playford RJ.
    Eur J Immunol; 2005 Aug 01; 35(8):2471-6. PubMed ID: 16021603
    [Abstract] [Full Text] [Related]

  • 28. HERC5, a HECT E3 ubiquitin ligase tightly regulated in LPS activated endothelial cells.
    Kroismayr R, Baranyi U, Stehlik C, Dorfleutner A, Binder BR, Lipp J.
    J Cell Sci; 2004 Sep 15; 117(Pt 20):4749-56. PubMed ID: 15331633
    [Abstract] [Full Text] [Related]

  • 29. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease.
    van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, Ahmad T, McGovern DP, Onnie C, Negoro K, Goldthorpe S, Foxwell BM, Mathew CG, Forbes A, Jewell DP, Playford RJ.
    Lancet; 2004 Sep 15; 365(9473):1794-6. PubMed ID: 15910952
    [Abstract] [Full Text] [Related]

  • 30. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha.
    Sancéau J, Falcoff R, Beranger F, Carter DB, Wietzerbin J.
    Immunology; 1990 Jan 15; 69(1):52-6. PubMed ID: 1690177
    [Abstract] [Full Text] [Related]

  • 31. Expression of nucleotide-binding oligomerization domain 2 in normal human dental pulp cells and dental pulp tissues.
    Lin ZM, Song Z, Qin W, Li J, Li WJ, Zhu HY, Zhang L.
    J Endod; 2009 Jun 15; 35(6):838-42. PubMed ID: 19482182
    [Abstract] [Full Text] [Related]

  • 32. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function.
    Mao L, Dhar A, Meng G, Fuss I, Montgomery-Recht K, Yang Z, Xu Q, Kitani A, Strober W.
    Front Immunol; 2022 Jun 15; 13():988862. PubMed ID: 36189261
    [Abstract] [Full Text] [Related]

  • 33. Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells.
    Okumura S, Yuki K, Kobayashi R, Okamura S, Ohmori K, Saito H, Ra C, Okayama Y.
    Clin Immunol; 2009 Feb 15; 130(2):175-85. PubMed ID: 18938111
    [Abstract] [Full Text] [Related]

  • 34. Characterization of nucleotide-binding oligomerization domain (NOD) protein expression in primary murine microglia.
    Sterka D, Marriott I.
    J Neuroimmunol; 2006 Oct 15; 179(1-2):65-75. PubMed ID: 16842862
    [Abstract] [Full Text] [Related]

  • 35. Functional interaction of CARD15/NOD2 and Crohn's disease-associated TNFalpha polymorphisms.
    Linderson Y, Bresso F, Buentke E, Pettersson S, D'Amato M.
    Int J Colorectal Dis; 2005 Jul 15; 20(4):305-11. PubMed ID: 15800781
    [Abstract] [Full Text] [Related]

  • 36. Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue.
    Darcissac EC, Bahr GM, Pouillart PR, Riveau GJ, Parant MA.
    Cytokine; 1996 Aug 15; 8(8):658-66. PubMed ID: 8894442
    [Abstract] [Full Text] [Related]

  • 37. Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation.
    Kurokawa T, Kikuchi T, Ohta K, Imai H, Yoshimura N.
    Ophthalmology; 2003 Oct 15; 110(10):2040-4. PubMed ID: 14522785
    [Abstract] [Full Text] [Related]

  • 38. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction.
    Yang Z, Fuss IJ, Watanabe T, Asano N, Davey MP, Rosenbaum JT, Strober W, Kitani A.
    Gastroenterology; 2007 Nov 15; 133(5):1510-21. PubMed ID: 17915219
    [Abstract] [Full Text] [Related]

  • 39. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.
    Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH.
    Proc Natl Acad Sci U S A; 2005 Nov 08; 102(45):16309-14. PubMed ID: 16260731
    [Abstract] [Full Text] [Related]

  • 40. Pro-inflammatory adjuvant properties of pigment-grade titanium dioxide particles are augmented by a genotype that potentiates interleukin 1β processing.
    Riedle S, Pele LC, Otter DE, Hewitt RE, Singh H, Roy NC, Powell JJ.
    Part Fibre Toxicol; 2017 Dec 08; 14(1):51. PubMed ID: 29216926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.